Related Experiment Video
Updated: Jan 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Anti-Androgen Abiraterone Acetate Improves the Therapeutic Efficacy of Statins on Castration-Resistant Prostate
Dannah R Miller1, Matthew A Ingersoll1, Yu-Wei Chou1,2
1Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Abstract:
The treatment of castration-resistant (CR) prostate cancer (PCa) is limited. A sub-population of CR PCa tumors can synthesize androgens for intracrine androgen receptor (AR) activation, thus targeting androgen biosynthesis could be an effective therapeutic option for these patients. We determined that androgen biosynthesis inhibitors simvastatin, atorvastatin, and ketoconazole directly inhibit growth, migration, and colony formation of LNCaP C-81 cells, which exhibit de novo androgen biosynthesis, with simvastatin being the most effective. Importantly, in combination treatments, statins specifically enhanced growth suppression with added effects by anti-androgen abiraterone acetate on the CR PCa cells. Thus, statins can be used in conjunction with abiraterone acetate to enhance anti-androgen therapy for CR PCa.
Insights
Statins like simvastatin inhibit castration-resistant prostate cancer (CR PCa) growth by targeting androgen synthesis. Combining statins with abiraterone acetate enhances anti-androgen therapy for CR PCa.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Castration-resistant prostate cancer (CR PCa) presents limited treatment options.
- Some CR PCa tumors sustain growth via intracrine androgen receptor (AR) activation through de novo androgen synthesis.
- Targeting androgen biosynthesis is a potential therapeutic strategy for CR PCa.
Purpose of the Study:
- To investigate the efficacy of androgen biosynthesis inhibitors, specifically statins (simvastatin, atorvastatin) and ketoconazole, against CR PCa cells.
- To evaluate the synergistic effects of statins in combination with the anti-androgen abiraterone acetate.
Main Methods:
- In vitro assessment of growth, migration, and colony formation inhibition in LNCaP C-81 cells (a model for de novo androgen synthesis in CR PCa).
- Evaluation of combination treatments involving statins and abiraterone acetate.
Main Results:
- Simvastatin, atorvastatin, and ketoconazole directly inhibited growth, migration, and colony formation of LNCaP C-81 cells.
- Simvastatin demonstrated the most potent inhibitory effect.
- Combination therapy with statins and abiraterone acetate showed enhanced growth suppression compared to individual treatments.
Conclusions:
- Statins are effective inhibitors of androgen biosynthesis in CR PCa cells.
- Statins can potentiate the effects of abiraterone acetate, suggesting a role in combination therapy to improve treatment outcomes for CR PCa.
Related Concept Videos
Treatment Resistant Cancers
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Self-Efficacy
Acetals and Thioacetals as Protecting Groups for Aldehydes and Ketones
In the presence of multiple functional groups, when selective reduction of one group over the other is desired, groups like aldehydes and ketones that form acetals...
Resistivity
Resistance

